3 Key Considerations for Implementing Biosimilars in Health Systems
Still, health systems are a critical channel not only to ensure biosimilars’ success, but also to ensure that patients, providers, and the collective healthcare system are receiving the full benefit of this new class of therapies. Manufacturers will need to work with hospital teams to develop a process to evaluate and support biosimilars as an addition to or replacement for reference products. That starts by understanding 3 key considerations for assisting health systems implementing biosimilars: safety and efficacy, operational support and economic impact, and workflow and access.
To read the full article, as originally published in The Center for Biosimilars, click here.
Coordinated Care: The Value of Patient and Provider Satisfaction within Health System Specialty Pharmacies
Download this new white paper from IHOC - Coordinated Care: The Value of Patient and Provider Satisfaction within Health System Specialty Pharmacies - to learn the key insights about the role HSSPs play in improving the patient experience and why patient and provider satisfaction are important data points for both payers and manufacturers to consider when deciding to include HSSPs in their networks.